Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Celgene Phase II (later renamed to IIa) trial for Otezla (apremilast), CC-10004-PSOR-003
Subjects: 260
Objective: evaluate doses 20 mg QD vs 20 mg BID vs placebo
PASI75 Response
placebo: 10.3 %
Otezla 20 mg QD : 10.3 %
Otezla 20 mg BID: 24.4 %
Conclusion: 20 mg QD crapped, 20 mg BID obviously warranted phase IIb with added dose of 30 mg BID.

But the really interesting stuff:
First Subject Enrolled: Apr 23 2006
Last Visit Completed: Feb 07 2007
Topline Announced: May 22, 2007 or about 100 days after the last patient visit. If this (IPIX) board can provide any insight then PSOR-003 trial must have failed around mid April, partially resurrected about May 1st (Labor day) just to fail again by mid May until the Lazarus day: May 22.

Were you failure whiners Celgene’s shareholders circa 2006/2007?